Genetic Regulation of Valproic Acid Teratogenicity

点击翻译按钮获取中文摘要

DESCRIPTION (provided by applicant): The in utero exposure to the pharmaceutical compound Depakene (Valproic Acid; VPA) increases the incidence of congenital malformations and neurodevelopmental defects in humans. The objective of this research proposal is to identify and characterize the genetic modifiers of VPA-induced neural tube defects (NTDs). The proposed research is conducted in mouse models, but the resultant data is expected to enable clinicians, under FDA approval, to develop personalized medicine strategies based on an the risk posed by homologous gene variants in human patient populations. This is increasingly important as VPA is now used not only in epilepsy therapy, but also to treat migraine headaches, and bipolar and schizoaffective disorders, increasing exposure to women of reproductive age. We hypothesize that the etiology of NTDs and neurodevelopmental deficits involves fetal genetic contributions, and that their protein products are modifying the ability of VPA to induce neural abnormalities. Specifically, we propose to test the hypothesis that variation within Acyl-CoA Synthetase Medium-Chain (ACSM) genes are more prevalent in mouse embryos with NTDs following exposure to teratogenic concentrations of VPA, than in similarly exposed embryos that appear normal. We propose to fine map the critical region on chromosome 7 in order to identify novel gene variants responsible for NTDs and neurodevelopmental deficits induced by VPA, using our established mouse models of VPA-teratogenesis. We propose to re-sequence all known genes mapped to the critical region in affected and unaffected mouse fetuses following in utero VPA exposure. A combination of Sanger sequencing and targeted resequencing by next-generation sequencing techniques, using targeted enrichment (NimbleGen Sequence Capture Arrays and Agilent Technologies SureSelect System) of samples will be used to thoroughly interrogate the VPA-sensitivity loci. The goal of target enrichment prior to next-generation sequencing is to expand upon our whole genome association studies to: 1) define SNPs and unique genomic variations; and 2) correlate these variants to VPA-induced neurodevelopmental disease. We will then develop novel ACSM mutant mouse lines using existing targeted embryonic stem cell clones and validate this gene family as regulating susceptibility to VPA-induced NTDs.